co-presented by
ASSOCIATE SPONSORS
co-presented by
ASSOCIATE SPONSORS
Glenmark Pharma's fourth quarter consolidated net profit rose a better-than-expected 11 percent year-on-year to Rs 167 crore, helped by growth across its generics business and specialty formulation business.
Quarterly Consolidated net sales climbed 25 percent from a year ago to to Rs 1,335 crore.
Analysts on an average had expected the Mumbai-based drug maker to report a net profit at Rs 150 crore, on net sales of Rs 1,240 crore, according to a CNBC-TV18 poll.
The company's generics business revenue was up 25 percent to Rs 587 crore in the fourth quarter. Revenue from specialty formulations, excluding out-licensing revenue, rose 25 percent to Rs 741 crore.
Glenmark shares closed at Rs 521.35 on NSE, up over 1 percent
Also Read: GSK Pharma Q1 net up 37% to Rs 169cr; shares rally
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
